Isotretinoin - Cipher Pharmaceuticals

Drug Profile

Isotretinoin - Cipher Pharmaceuticals

Alternative Names: Absorica; CIP-isotretinoin; Epuris; Isotretinoin - Cipher; Lisacne-CIP; Semi-liquid isotretinoin capsules - Cipher

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cipher Pharmaceuticals
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jul 2015 Cipher has patent protection for isotretinoin in USA
  • 24 Apr 2015 Cipher Pharmaceuticals has three issued patents and three patents pending for isotretinoin in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top